Company research
Obsidian Therapeutics, Inc.
CIK 2130606Updated Sep 27, 2026
SecurityOBX · NASDAQ · equity
Name history
Gazelle Parent, Inc. · through Aug 3, 2026
OBX price & chart
Loading TradingView…
NASDAQ:OBX on TradingView ↗About the company
Obsidian Therapeutics, Inc. is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian’s proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian has offices in Cambridge and Bedford, MA. For more information, please visit www.obsidiantx.com.
In the news
No coverage from other publishers is available.
Recent filings
Offerings
Registration 333-298642
Registration 333-295249
Filing attachments
d309963dex107.htm · 8-K · 2026-08-03
EX-10.7 11 d309963dex107.htm EX-10.7 EX-10.7 Exhibit 10.7 OBSIDIAN THERAPEUTICS, INC. 2026 EQUITY INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Obsidian Therapeutics, Inc. 2026 Equity Incentive Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Obsidian Therapeutics, Inc. (the “Company”) and its Affiliates upon whose judgmen…
Read attachment ↗d309963dex41.htm · 8-K · 2026-08-03
EX-4.1 4 d309963dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 GALERA THERAPEUTICS, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ● ] Warrant Shares: Initial Exercise Date: February 17, 2023 ───────────────────────────────────────────────── THIS WARRANT TO PURCHASE COMMON STOCK (this “Warrant”) certifies that, for value received, [ ● ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se…
Read attachment ↗d309963dex991.htm · 8-K · 2026-08-03
EX-99.1 21 d309963dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million Obsidian Therapeutics to focus on the advancement of its pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors Post-transaction cash, cash equivalents and investments of approximately $350 million expected to fund operations into 2H 2028, inclu…
Read attachment ↗d309963dex992.htm · 8-K · 2026-08-03
EX-99.2 22 d309963dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 RISK FACTORS You should carefully consider the following risk factors. These risk factors are not exhaustive, and investors are encouraged to perform their own investigation with respect to the businesses of Obsidian. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may adversely affect the ability to realize the anticipated ben…
Read attachment ↗d117787dex107.htm · S-4/A · 2026-06-30
EX-10.7 5 d117787dex107.htm EX-10.7 EX-10.7 Exhibit 10.7 OBSIDIAN THERAPEUTICS, INC. 2026 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Obsidian Therapeutics, Inc. 2026 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Obsidian Therapeutics, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of Stock (as defined in Section 11). A number of shares of Stock equal to the lesser of (x) 1% of the numb…
Read attachment ↗d117787dex107.htm · S-4/A · 2026-06-24
EX-10.7 4 d117787dex107.htm EX-10.7 EX-10.7 Exhibit 10.7 OBSIDIAN THERAPEUTICS, INC. 2026 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Obsidian Therapeutics, Inc. 2026 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Obsidian Therapeutics, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of Stock (as defined in Section 11). A number of shares of Stock equal to the lesser of (x) 1% of the numb…
Read attachment ↗